Amplified
Attention for Alzheimer’s Disease Diagnostic Market to Create Ample Growth
Prospects.
Global
Alzheimer’s Disease Diagnostic Market – Overview:
The
wide spread detection of Alzheimer’s disease in various areas of the world as
well as its detection in diverse demographics have prompted the expansion of
the sector. Market reports linked to the healthcare sector made available by
Market Research Future along with published reports on other sectors have been
recently issued along with a report on this market. The industry is expected to
attain USD 12 billion in revenues by the end of the forecasted period while
expanding at a CAGR of 10 percent in the forecast period.
The
ability to detect Alzheimer’s in the initial stages can help in a major way to
control the progression of the disease. However, increase in the geriatric
segment of the population has increased in the number of cases that are being
detected around the world. Rise in the level of medical breakthroughs made
towards understanding the disease have enabled the discovery of new methods for
detection. Additionally, discoveries of new drugs that can potentially control
Alzheimer’s are also increasing gradually, which is beneficial for the
development of this market especially through the forecast period 2018 to 2022.
Alzheimer’s
Disease Industry Segments:
The
industry for Alzheimer’s disease diagnostics globally on the basis of type has
been segmented into late-onset Alzheimer's disease, early-onset Alzheimer's
disease, familial Alzheimer's disease and more. The end users category segments
the market into hospitals, clinics, diagnostic centers and others. The
diagnostic test segment of the industry comprises of mini-mental state exam
(MMSE), genetic testing, neurological exam, brain imaging and others.
Alzheimer’s
Disease Diagnostic Market Detailed Regional Analysis
The
regional analysis for Alzheimer’s disease diagnostic market includes regions
such as Europe, Asia Pacific, North America and rest of the world. The North
American region held the major market share in Alzheimer’s disease diagnostic
globally in 2015. The North American region for Alzheimer’s disease diagnostics
is anticipated to reach USD 12 Million by the end of the forecast period. The
European region is the second major industry for Alzheimer’s disease diagnostic
industry. The Asia Pacific is estimated to be the most rapidly growing region
of the Alzheimer’s disease diagnostic industry in the forecast period.
Contenders
who are a part of the industry have devised their corporate strategy blueprint
in a way that that can bring the best outcomes for development in the current
scenario. With the ability to sustain their competitive edge being one of the
primary factors driving their efforts, the scope for growth in the industry
appears to be promising through the forecast period. The rising affinity for
diversification in the market, has indirectly enabled the players to utilize
the many prospects available. The companies in this particular industry are
also trying to maintain and enhance financial liquidity that can be
instrumental to invest in growth strategies as and when they become available.
This particular trend has empowered portfolio improvements along with the
affinity for diversification in the sector, which has helped the market
competitors tremendously in this industry.
The
prominent contenders in the market for Alzeihmer’s disease diagnostic market
are Neuro-Bio Ltd (UK), TauRx (Republic of Singapore), Accera, Inc. (US),
Alector LLC (US), Treventis Corporation (US), Eli Lilly and Company (UK),
Cognition Therapeutics Inc. (US) among others.
Alzheimer’s
Disease Diagnostic Industry Updates:
A
group of researchers are on the verge of developing a blood test that can spot
Alzheimer's disease long before symptoms appear. The test will be exceptionally
useful for scientists trying to understand and treat Alzheimer’s. A study which
was made available in the EMBO Molecular Medicine journal has discovered a
potential solution to this important problem. By the use of immuno-infrared
sensor technology which is based on an antibody is the basis for the test’s
fuctionality. The sensor is used to extract all amyloid-beta from the blood
sample. The researchers can measure the comparative levels unhealthy and of
healthy protein due to the dual versions of beta-amyloid that are taken in
infrared light at various permitted frequencies.
About
US:
Market Research Future (MRFR), enable customers to
unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact
Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone:
+1
646 845 9312
Email: sales@marketresearchfuture.com
No comments:
Post a Comment